As previous reviews have focused on either BCG or anti‐PD‐1/PD‐L1 immunotherapies, rarely both, here we review bladder cancer BCG and anti‐PD1/PD‐L1 immunotherapies together to explore our knowledge and the potential to improve immunotherapy. Here, PDCD1 is linked to urinary bladder carcinoma.